GlobeNewsWire · 14 Sept 2026neutral
Onconetix provided an initial advance of $2.5 million to Realbotix LLC as a strategic bridge financing facility to support growth and working capital in advance of its pending acquisition of Realbotix. The non-interest bearing facility will be automatically cancelled and discharged in full upon closing of the acquisition.
Why it matters — ONCO watchers would care because this financing supports Realbotix's operations ahead of the pending acquisition, which could affect the timing and completion of the deal.
GlobeNewsWire · 14 Sept 2026positive
Onconetix provided an initial advance of $2.5 million to Realbotix LLC under a non-interest-bearing bridge financing facility to support growth and working capital. The facility is automatically cancelled and discharged in full upon closing of the pending acquisition of Realbotix by Onconetix.
Why it matters — ONCO watchers would care because this financing move signals continued progress and support toward the closing of Onconetix's pending acquisition of Realbotix LLC.
GlobeNewsWire · 3 Sept 2026positive
Realbotix, which Onconetix has agreed to acquire, launched a pilot with a leading European telecommunications company to deploy humanoid robots as presenters, hosts, and brand ambassadors in live presentations and events. The pilot extends Realbotix's robot capabilities beyond one-on-one interaction into dynamic, audience-facing environments.
Why it matters — For Onconetix watchers, this milestone reflects growing commercial traction for the acquisition target ahead of the planned transaction, expanding Realbotix's use cases into larger-scale deployment settings.
GlobeNewsWire · 6 Aug 2026positive
Realbotix, the target of Onconetix's pending acquisition, entered into an agreement with a streaming platform to feature one of its humanoid robots as a robotic character in an upcoming episode of a popular Emmy-award-winning television series. Onconetix recently signed a definitive agreement to acquire Realbotix LLC, a subsidiary of Realbotix Corp.
Why it matters — ONCO watchers would care because the agreement reflects real-world adoption of humanoid robotics technology across education, healthcare, hospitality, and customer engagement, relating to the company's pending acquisition of Realbotix.
GlobeNewsWire · 5 Aug 2026positive
Onconetix, Inc. announced that its fully-owned Swiss subsidiary, Proteomedix AG, appointed co-founder and Proclarix co-developer Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting on June 22, 2026, where Thomas Meier, PhD was re-elected Chairman for an additional one-year term.
Why it matters — The appointment brings a co-founder and Proclarix co-developer back to the board of Onconetix's Swiss subsidiary, adding relevant expertise at the subsidiary level.
